296 related articles for article (PubMed ID: 20014021)
1. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
[TBL] [Abstract][Full Text] [Related]
10. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ; Abreu MT; D'Haens G; Colombel JF; Vermeire S; Mitchev K; Jamoul C; Fedorak RN; Spehlmann ME; Wolf DC; Lee S; Rutgeerts P
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
Sandborn WJ; Lee SD; Randall C; Gutierrez A; Schwartz DA; Ambarkhane S; Kayhan C; Pierre-Louis B; Schreiber S; Lichtenstein GR
Aliment Pharmacol Ther; 2014 Oct; 40(8):903-16. PubMed ID: 25146586
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Allez M; Vermeire S; Mozziconacci N; Michetti P; Laharie D; Louis E; Bigard MA; Hébuterne X; Treton X; Kohn A; Marteau P; Cortot A; Nichita C; van Assche G; Rutgeerts P; Lémann M; Colombel JF
Aliment Pharmacol Ther; 2010 Jan; 31(1):92-101. PubMed ID: 19709098
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
19. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
